头颈部黏膜鳞癌免疫检查点抑制剂治疗相关不良事件与健康相关生活质量的范围综述
该范围综述纳入98项研究,考察头颈部鳞状细胞癌(HNSCC)患者接受免疫检查点抑制剂(ICI)治疗的治疗相关不良事件(TRAE)与健康相关生活质量(HRQoL)。中重度TRAE发生率低于10%,多数为轻度影响;皮肤、内分泌、肺、肝、胃肠及全身性主诉在超过40%的研究中有报告。ICI单药毒性低于多模式治疗,联合ICI仅轻微增加TRAE;HRQoL评分较低且治疗期间变化不大。
要点
- 中重度TRAE发生率低于10%,多数患者仅受轻度影响。
- 皮肤、内分泌、肺、肝、胃肠及全身性不良事件在超过40%的研究中报告。
- ICI单药毒性低于多模式治疗,联合ICI仅轻微增加TRAE。
核心结论
- ICI用于HNSCC总体耐受良好,但TRAE常见且可能带来长期功能后果。
- 需要灵活的支持性照护路径以助早期发现和个体化管理功能影响。
研究设计与样本
- 范围综述,纳入98项研究。
主要发现
- 中重度TRAE发生率低于10%,多数患者经历轻度影响。
- 皮肤、内分泌、肺、肝、胃肠及全身性主诉在超过40%的研究中有报告,多数症状发生于治疗期间。
- ICI单药报告毒性低于多模式治疗,联合ICI仅轻微增加TRAE。
- HRQoL评分较低,且在ICI治疗期间变化不大。
关键数值与推荐
- 中重度TRAE发生率低于10%。
- 皮肤、内分泌、肺、肝、胃肠及全身性主诉在超过40%的研究中报告。
临床怎么用
- 临床应关注HNSCC患者ICI治疗期间常见TRAE,尤其皮肤、内分泌、肺、肝及胃肠事件。
- 支持性照护应灵活设计,以早期发现和个体化管理功能影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill-defined. Hence, known treatment-related adverse events (TRAEs) and health-related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care services. METHODS: Scoping review including 98 studies. RESULTS: Moderate-severe TRAEs occurred at < 10% incidence, with most experiencing mild impacts. Dermatologic, endocrine, pulmonary, hepatic, gastrointestinal, and constitutional complaints were reported in > 40% of studies, with most symptoms occurring during treatment. ICI monotherapy had less reported toxicity than multimodality treatments. Adding ICIs to multimodality treatment creates a minimal increase in TRAEs. HRQoL scores were low, with little change during ICI treatment. CONCLUSIONS: ICIs for HNSCC are generally well tolerated; however, TRAEs are common and may carry long-term functional consequences. Flexible supportive care pathways are needed to assist early detection and individualized management of functional impacts to optimize survivorship.
引用
- O'Donnell ND, Ward EC, Wishart LR, et al. Treatment-Related Adverse Events and Health-Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review. Head Neck. 2026. PMID: 42226019. doi:10.1002/hed.70306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。